TheraRadar
Landscape Ophthalmology

Glaucoma Clinical Trial Landscape

Data updated: May 20, 2026

515 clinical trials tracked since 2008

Glaucoma is being studied across 515 clinical trials registered since 2008, with 63 programs currently active. The competitive pipeline includes 18 active Phase 3 trials, 18 active Phase 2 trials, and 16 active Phase 1 trials. Top industry sponsors include Glaukos Corporation, AbbVie, SpyGlass Pharma, Inc..

63 active
/
515 total (since 2008)
16
Phase 1 Active
82 total
18
Phase 2 Active
160 total
18
Phase 3 Active
146 total
21
Phase 4 Active
173 total

Top Industry Sponsors

Sorted by active Active Done Failed
Glaukos Corporation 5 15 0
AbbVie 4 41 3
SpyGlass Pharma, Inc. 3 0 0
Qlaris Bio, Inc. 2 7 0
PolyActiva Pty Ltd 2 3 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06822738 RECRUITING
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
AbbVie n=130
NCT07354516 RECRUITING
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Qlaris Bio, Inc. n=60
NCT07495852 RECRUITING
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaukos Corporation n=510
NCT07075718 RECRUITING
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaukos Corporation n=610
NCT06066645 RECRUITING
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
Glaukos Corporation n=230

+ 141 more Phase 3 trials — see full database below

Glaucoma — Trials Started by Year (last 10 years)

2016
26
2017
15
2018
20
2019
21
2020
14
2021
22
2022
17
2023
16
2024
19
2025
22
2026
12

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Glaukos Corporation
20
AbbVie
48
SpyGlass Pharma, Inc.
3
Qlaris Bio, Inc.
9
PolyActiva Pty Ltd
5
Amneal Pharmaceuticals, LLC
2
Santen Pharmaceutical Co., Ltd.
10
Laboratoires Thea
9
Bausch & Lomb Incorporated
8
EyeD Pharma
2

Active Trials by Phase

Phase 1
16
Phase 2
18
Phase 3
18
Phase 4
21

Enrollment Size Distribution

1-50
179
51-200
204
201-500
73
501-1k
34
1k+
5

All Industry Sponsors

Sorted by active Active Done Failed
Glaukos Corporation 5 15 0
AbbVie 4 41 3
SpyGlass Pharma, Inc. 3 0 0
Qlaris Bio, Inc. 2 7 0
PolyActiva Pty Ltd 2 3 0
Amneal Pharmaceuticals, LLC 2 0 0
Santen Pharmaceutical Co., Ltd. 1 9 0
Laboratoires Thea 1 8 0
Bausch & Lomb Incorporated 1 7 0
EyeD Pharma 1 0 1
IVIEW Therapeutics Inc. 1 0 0
Life Biosciences Inc. 1 0 0
Rheon Medical SA 1 0 0
Huons Co., Ltd. 1 0 0
Perfuse Therapeutics, Inc. 1 0 0
NCT06822738 RECRUITING
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
AbbVie n=130
NCT07354516 RECRUITING
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Qlaris Bio, Inc. n=60
NCT07495852 RECRUITING
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaukos Corporation n=510
NCT07075718 RECRUITING
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaukos Corporation n=610
NCT06066645 RECRUITING
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
Glaukos Corporation n=230
NCT07335211 RECRUITING
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Huons Co., Ltd. n=206
NCT05695027 ACTIVE NOT RECRUITING
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
Columbia University n=250
NCT03933631 RECRUITING
Pilocarpine Use After Kahook Goniotomy
Montefiore Medical Center n=142
NCT07218796 RECRUITING
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
SpyGlass Pharma, Inc. n=400
NCT07218783 RECRUITING
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
SpyGlass Pharma, Inc. n=400
NCT03891446 ACTIVE NOT RECRUITING
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie n=455
NCT06666855 ACTIVE NOT RECRUITING
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
Santen Pharmaceutical Co., Ltd. n=345
NCT06731582 ENROLLING BY INVITATION
Nicotinamide Supplementation in Glaucoma
Singapore Eye Research Institute n=520
NCT06680245 NOT YET RECRUITING
Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery
St. Joseph's Healthcare Hamilton n=144
NCT06061718 ACTIVE NOT RECRUITING
Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Glaukos Corporation n=60
NCT05405868 RECRUITING
Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial
University College, London n=496
NCT05710198 RECRUITING
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
Omikron Italia S.r.l. n=1,000
NCT05401357 RECRUITING
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Amneal Pharmaceuticals, LLC n=168
NCT07082816 COMPLETED
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Alcon Research n=489
NCT05411198 COMPLETED
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
AbbVie n=74
NCT04630808 COMPLETED
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Nicox Ophthalmics, Inc. n=696
NCT05938699 COMPLETED
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution
Nicox Ophthalmics, Inc. n=18
NCT02390284 TERMINATED
Stop Retinal Ganglion Cell Dysfunction Study
University of Miami n=28
NCT03850782 COMPLETED
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
AbbVie n=515
NCT04445519 COMPLETED
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Nicox Ophthalmics, Inc. n=691
NCT06431113 COMPLETED
Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma
Fondazione IRCCS Policlinico San Matteo di Pavia n=40
NCT04944290 COMPLETED
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Padagis LLC n=447
NCT05583474 COMPLETED
OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
Otsuka Beijing Research Institute n=204
NCT03193333 TERMINATED
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Laboratorios Sophia S.A de C.V. n=51
NCT03868124 COMPLETED
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Glaukos Corporation n=560
NCT03519386 COMPLETED
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Glaukos Corporation n=590
NCT05397600 COMPLETED
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Laboratoires Thea n=684
NCT05503901 COMPLETED
A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension
Santen Pharmaceutical Co., Ltd. n=131
NCT02801617 TERMINATED
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Laboratorios Sophia S.A de C.V. n=116
NCT02507687 COMPLETED
Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
AbbVie n=240
NCT02981446 COMPLETED
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
Santen Pharmaceutical Co., Ltd. n=370
NCT03235232 COMPLETED
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
EMS n=406
NCT05022004 COMPLETED
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Sun Pharmaceutical Industries Limited n=599
NCT05495061 COMPLETED
A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Santen Pharmaceutical Co., Ltd. n=325
NCT03825380 COMPLETED
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
Laboratoires Thea n=485
NCT05042609 COMPLETED
A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
Tarsier Pharma n=142
NCT05973305 COMPLETED
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
Jadran Galenski laboratorij d.d. n=118
NCT05973318 COMPLETED
Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL
Jadran Galenski laboratorij d.d. n=110
NCT04061044 COMPLETED
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
Ocular Therapeutix, Inc. n=40
NCT04285580 COMPLETED
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
AbbVie n=37
NCT03362931 COMPLETED
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
Allergan n=65
NCT02617459 COMPLETED
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. n=366
NCT01722604 COMPLETED
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
Bausch & Lomb Incorporated n=258
NCT04024072 COMPLETED
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
Padagis LLC n=495
NCT04620135 COMPLETED
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals n=245
NCT04890106 COMPLETED
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma
Mankind Pharma Limited n=310
NCT05127525 TERMINATED
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
iRenix Medical, Inc. n=5
NCT04005079 WITHDRAWN
Pilocarpine After Combined Cataract/Trabectome Surgery
Montefiore Medical Center
NCT02636946 COMPLETED
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
Allergan n=144
NCT03450629 COMPLETED
Evaluation of Safety and Efficacy of PDP-716
Sun Pharma Advanced Research Company Limited n=682
NCT03284853 COMPLETED
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals n=436
NCT03927443 WITHDRAWN
A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
Sun Pharmaceutical Industries Limited
NCT04563559 WITHDRAWN
PREFERENTIAL Study
Duke University
NCT02914509 COMPLETED
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
Ocular Therapeutix, Inc. n=565
NCT02767219 COMPLETED
The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery
Moorfields Eye Hospital NHS Foundation Trust n=6
NCT02250651 COMPLETED
Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension
Allergan n=528
NCT02731118 TERMINATED
Antisecretory Factor (AF) Effects on Intraocular-pressure
St. Erik Eye Hospital n=50
NCT00945958 COMPLETED
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
Sun Pharma Advanced Research Company Limited n=161
NCT00947661 COMPLETED
Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension
Sun Pharma Advanced Research Company Limited n=578
NCT00716859 COMPLETED
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=139
NCT04052269 SUSPENDED
Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS)
Imperial College London n=30
NCT04455126 COMPLETED
Preservative-free Tafluprost Eye Drops in Newly Diagnosed Patients With Glaucoma
Alexandria University n=30
NCT02247804 COMPLETED
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Allergan n=594
NCT03639675 COMPLETED
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
Bayer n=16
NCT02512042 COMPLETED
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
Actavis Inc. n=973
NCT03257813 COMPLETED
Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)
Laboratorios Sophia S.A de C.V. n=60
NCT03419975 COMPLETED
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
Taejoon Pharmaceutical Co., Ltd. n=146
NCT01908816 COMPLETED
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
Novartis Pharmaceuticals n=270
NCT02558400 COMPLETED
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals n=718
NCT02674854 COMPLETED
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals n=750
NCT01099774 COMPLETED
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Allergan n=597
NCT01749930 COMPLETED
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Bausch & Lomb Incorporated n=420
NCT01749904 COMPLETED
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Bausch & Lomb Incorporated n=420
NCT01254604 COMPLETED
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
Merck Sharp & Dohme LLC n=190
NCT02059278 COMPLETED
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Nephron Pharmaceuticals Corporation n=335
NCT01895972 COMPLETED
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
Bausch & Lomb Incorporated n=130
NCT00853905 COMPLETED
Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?
Wills Eye n=77
NCT00853073 COMPLETED
Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
Wills Eye n=63
NCT02339584 COMPLETED
Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Alcon Research n=493
NCT02207491 COMPLETED
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals n=411
NCT02246764 COMPLETED
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals n=93
NCT02207621 COMPLETED
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Aerie Pharmaceuticals n=756
NCT02558374 COMPLETED
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals n=708
NCT00626782 COMPLETED
Lucentis Versus Mitomycin C During Glaucoma Surgery
Wills Eye n=24
NCT02822729 COMPLETED
A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study
Santen Pharmaceutical Co., Ltd. n=125
NCT02822742 COMPLETED
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
Santen Pharmaceutical Co., Ltd. n=26
NCT02623738 COMPLETED
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
Santen Pharmaceutical Co., Ltd. n=253
NCT02396316 COMPLETED
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
Bayer n=54
NCT01026831 COMPLETED
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
Merck Sharp & Dohme LLC n=643
NCT02278614 COMPLETED
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
Laboratoires Thea n=242
NCT01217606 COMPLETED
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Allergan n=185
NCT02565173 COMPLETED
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Inotek Pharmaceuticals Corporation n=303
NCT02901236 COMPLETED
Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma
Athens Vision Eye Institute n=40
NCT00901108 TERMINATED
Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma
University of Alberta n=19
NCT01640756 COMPLETED
AqueSys Microfistula Implant in Refractory Glaucoma
AqueSys, Inc. n=60
NCT02641457 COMPLETED
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Instituto de Olhos de Goiania n=2
NCT02105285 COMPLETED
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Otsuka Pharmaceutical Co., Ltd. n=193
NCT02105272 COMPLETED
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Otsuka Pharmaceutical Co., Ltd. n=237
NCT01426113 TERMINATED
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
Allergan n=6
NCT01652664 COMPLETED
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Alcon Research n=184
NCT01342094 COMPLETED
DE-111 Against Timolol Ophthalmic Solution 0.5%
Santen Pharmaceutical Co., Ltd. n=166
NCT01343082 COMPLETED
DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Santen Pharmaceutical Co., Ltd. n=148
NCT01342081 COMPLETED
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
Santen Pharmaceutical Co., Ltd. n=489
NCT01052558 COMPLETED
GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma
Glaukos Corporation n=164
NCT01830140 COMPLETED
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Allergan n=466
NCT01156012 COMPLETED
Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients
Laboratoires Thea n=404
NCT01721707 WITHDRAWN
Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
Adapt Produtos Oftalmológicos Ltda.
NCT01241240 COMPLETED
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Allergan n=192
NCT00928590 COMPLETED
Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension
Alcon Research n=155
NCT00760539 COMPLETED
Safety and Efficacy of Travoprost/Timolol BAC-free
Alcon Research n=87
NCT00672997 COMPLETED
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
Alcon Research n=301
NCT00892762 COMPLETED
Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health
Alcon Research n=434
NCT01357616 COMPLETED
Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension
Alcon Research n=328
NCT01309204 COMPLETED
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
Alcon Research n=1,184
NCT01310777 COMPLETED
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension
Alcon Research n=771
NCT01263834 COMPLETED
Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
Prince of Songkla University n=39
NCT01453855 COMPLETED
Travoprost 3-Month Safety and Efficacy Study
Alcon Research n=1,099
NCT01216943 COMPLETED
Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension
Allergan n=126
NCT01284166 WITHDRAWN
Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Allergan
NCT01297920 COMPLETED
Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%
Alcon Research n=1,062
NCT01087671 COMPLETED
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
Santen Oy n=185
NCT01297517 COMPLETED
Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%
Alcon Research n=1,001
NCT01177098 COMPLETED
Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Allergan n=561
NCT00872651 COMPLETED
Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Alcon Research n=242
NCT01292460 COMPLETED
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
Santen Oy n=600
NCT00691717 COMPLETED
Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension
Alcon Research n=201
NCT00767494 TERMINATED
Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT
Alcon Research n=17
NCT00690794 COMPLETED
Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension
Alcon Research n=726
NCT00912054 TERMINATED
DuoTrav APS Versus XALACOM® in Ocular Surface Health
Alcon Research n=240
NCT00767481 TERMINATED
1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
Alcon Research n=6
NCT01306461 COMPLETED
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
Santen Oy n=401
NCT00705770 WITHDRAWN
A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
Alcon Research
NCT00761319 COMPLETED
Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health
Alcon Research n=705
NCT00848536 COMPLETED
Efficacy Study of Travoprost APS Versus TRAVATAN
Alcon Research n=371
NCT01544192 COMPLETED
Impact of Oral Versatile Antioxidants on Glaucoma Progression
Bagcilar Training and Research Hospital n=60
NCT01452009 WITHDRAWN
Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%
Alcon Research
NCT00862472 WITHDRAWN
Safety and Efficacy Study of DuoTrav APS Versus DuoTrav
Alcon Research
NCT01168414 COMPLETED
A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Ministry of Health, Malaysia n=42
NCT00878917 COMPLETED
Equivalence Study of Dorzolamide 2% Eye Drops Solution
Alfred E. Tiefenbacher (GmbH & Co. KG) n=32
NCT00709449 COMPLETED
An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects
Medical University of Vienna n=60
NCT00596791 COMPLETED
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
Santen Oy n=150

Full Glaucoma Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only